Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patient...
Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816
About this item
Full title
Author / Creator
Mitsudomi, Tetsuya , Ito, Hiroyuki , Okada, Morihito , Sugawara, Shunichi , Shio, Yutaka , Tomii, Keisuke , Okami, Jiro , Sakakura, Noriaki , Kubota, Kaoru , Takamochi, Kazuya , Atagi, Shinji , Tsuboi, Masahiro , Oizumi, Satoshi , Ikeda, Norihiko , Ohde, Yasuhisa , Ntambwe, Ives , Mahmood, Javed , Cai, Junliang and Tanaka, Fumihiro
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
In the open‐label, phase III CheckMate 816 study (NCT02998528), neoadjuvant nivolumab plus chemotherapy demonstrated statistically significant improvements in event‐free survival (EFS) and pathological complete response (pCR) versus chemotherapy alone in patients with resectable non‐small‐cell lung cancer (NSCLC). Here we report efficacy and safety...
Alternative Titles
Full title
Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from CheckMate 816
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10859619
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10859619
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.16030
